CALGARY, May 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (“Oncolytics”) has been granted U.S. Patent 7,052,832 entitled “Methods for the Treatment of Cellular Proliferative Disorders.” The claims describe methods of identifying the susceptibility of cells to reovirus infection.
“This patent provides coverage for methods of identifying patients that should have a high likelihood of response to reovirus treatment, by measuring Ras-MAP signaling through biopsies or other biological samples collected from those patients,” said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. “This could be of importance in the future development of REOLYSIN(R).”
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation. For further information about Oncolytics, please visit www.oncolyticsbiotech.com
This news release contains forward looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements, including among others, the Company’s belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company’s expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company’s business and technologies, involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.
Oncolytics Biotech Inc.
CONTACT: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW,Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403) 283-0858,cathy.ward@oncolytics.ca, www.oncolyticsbiotech.com; The Equicom Group,Nick Hurst, 20 Toronto Street, Toronto, Ontario, M5C 2B8, Tel: (416)815-0700 ext.226, Fax: (416) 815-0080, nhurst@equicomgroup.com; TheInvestor Relations Group, Damian McIntosh, 11 Stone St, 3rd Floor, NewYork, NY, 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,dmcintosh@investorrelationsgroup.com; RenMark Financial Communications,John Boidman, 2080 Rene Levesque Blvd. W., Montreal, PQ, H3H 1R6, Tel:(514) 939-3989, Fax: (514) 939-3717, jboidman@renmarkfinancial.com